Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIPHETAMINE 12.5 vs AZASITE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Biphetamine 12.5 is a central nervous system stimulant that increases the levels of norepinephrine and dopamine in the synaptic cleft by inhibiting the reuptake of these neurotransmitters and by promoting their release from presynaptic terminals.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Treatment of bacterial conjunctivitis caused by susceptible organisms
12.5 mg orally once daily in the morning, may titrate weekly by 12.5 mg to maximum 75 mg/day.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
9-14 hours in children and adolescents; clinical effects typically last 4-6 hours due to distribution and tolerance. Terminal half-life may be longer in adults with higher body fat (up to 20 hours).
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Hepatic metabolism via CYP2D6 and other pathways; primarily deamination and oxidation.
Not significantly metabolized; primarily excreted unchanged in bile and urine.
Renal: 70-80% as unchanged drug and metabolites (primarily deaminated metabolites); fecaroute is negligible. Urinary p H-dependent: acidification increases renal clearance, alkalinization decreases it.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
20-40%, primarily to albumin and alpha-1 acid glycoprotein.
~50-60% bound to plasma proteins (primarily albumin).
3.2-5.6 L/kg, indicating extensive tissue distribution; crosses blood-brain barrier readily.
Vd: ~100 L/kg (extensive tissue penetration; not meaningful for topical use; systemic Vd based on IV data).
Oral: 75-100% (amphetamines have high and consistent oral bioavailability).
Ophthalmic: negligible systemic absorption (<10% of topical dose) due to low corneal permeability and dilution by tears.
GFR <30 m L/min: avoid use; GFR 30-60 m L/min: reduce dose by 50% and monitor; GFR >60 m L/min: no adjustment.
No dosage adjustment required for ophthalmic use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No dosage adjustment required for ophthalmic use.
6-12 years: 6.25 mg or 12.5 mg once daily in the morning, may increase by 6.25 mg weekly up to 37.5 mg/day; weight-based: 0.3-0.8 mg/kg/day, max 37.5 mg/day.
Safety and efficacy in pediatric patients have not been established; limited data available.
Initiate at 6.25 mg once daily in the morning, increase cautiously by 6.25 mg weekly; monitor for cardiovascular and psychiatric effects; maximum daily dose 37.5 mg.
No specific dosage adjustment recommended; use same dosing as for adults.
Biphetamine has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular events.
None
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Risk of hypertension and tachycardia,Risk of psychiatric adverse events such as exacerbation of pre-existing psychosis, mania, or aggression,Risk of seizures in patients with a history of seizures,Long-term suppression of growth in children
Prolonged use may result in overgrowth of nonsusceptible organisms,Contact lens should not be worn during treatment,Do not inject subconjunctivally or introduce into the anterior chamber
History of drug abuse,Cardiovascular disease including symptomatic cardiovascular disease, advanced arteriosclerosis, hypertension, hyperthyroidism,Glaucoma,Agitated states,History of seizures or tics,Concomitant use of MAOIs or within 14 days of MAOI use
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,Hypersensitivity to any component of the formulation
Avoid high-fat meals as they may delay absorption. Limit caffeine intake (coffee, tea, colas) as it may increase stimulant effects and risk of side effects. Acidic foods/juices (e.g., orange juice, grapefruit juice) can decrease absorption; take medication with water. Maintain adequate hydration.
No clinically significant food interactions. Administer with or without food as per dosing instructions.
First trimester: Possible increased risk of congenital malformations (e.g., heart defects, oral clefts) based on limited human data; animal studies show fetal abnormalities. Second and third trimesters: Risk of prematurity, low birth weight, and neonatal withdrawal symptoms (e.g., irritability, poor feeding). Amphetamines may cause vasoconstriction leading to placental insufficiency.
Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observed in animal studies at doses up to 200 mg/kg/day (systemic). Limited human data; risk is considered low. First trimester: unlikely to cause major malformations. Second and third trimesters: no specific risks identified.
Biphetamine is excreted into breast milk. M/P ratio is approximately 2.5–7.5. Use is contraindicated during breastfeeding due to potential for adverse effects on infant development (e.g., irritability, poor weight gain).
Azithromycin is excreted into human milk after systemic administration; the M/P ratio is approximately 0.90. After ophthalmic administration, systemic absorption is minimal, resulting in negligible exposure to the infant. Considered compatible with breastfeeding; use with caution if eye drops are applied multiple times daily.
No established guidelines; avoid use in pregnancy. If unavoidable, use lowest effective dose with careful monitoring. Increased clearance may necessitate higher doses, but risks outweigh benefits.
No dose adjustment is necessary for ophthalmic use in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) do not significantly affect topical ocular drug levels due to negligible systemic absorption.
Biphetamine 12.5 is a mixed amphetamine salt product (D-amphetamine and L-amphetamine). Monitor for cardiovascular events, especially in patients with pre-existing conditions. Avoid use within 14 days of MAOIs. Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Assess for tics or Tourette's syndrome. Monitor growth in pediatric patients. May cause withdrawal symptoms upon abrupt discontinuation.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic used for bacterial conjunctivitis. Shake well before each use. Avoid contact with contact lenses during treatment. Do not use for more than 14 days. Monitor for signs of hypersensitivity.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid taking late in the day to prevent insomnia.,Report any chest pain, shortness of breath, or fainting immediately.,May cause dizziness or blurred vision; avoid driving until you know how the medication affects you.,Do not stop abruptly; your doctor will taper the dose to avoid withdrawal symptoms.,Inform your doctor if you have a history of heart problems, high blood pressure, seizures, or mental health conditions.,Avoid alcohol and other CNS stimulants.,Store at room temperature away from moisture and heat.
Shake the bottle well before each use.,Wash hands before and after application.,Do not touch the dropper tip to any surface.,Remove contact lenses before use; do not reinsert during treatment.,Instill the prescribed number of drops in the affected eye(s).,Avoid wearing eye makeup during treatment.,Finish the entire course of medication even if symptoms improve.,Report any worsening, itching, or swelling to your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIPHETAMINE 12.5 vs AZASITE, answered by our medical review team.
BIPHETAMINE 12.5 is a Central Nervous System Stimulant that works by Biphetamine 12.5 is a central nervous system stimulant that increases the levels of norepinephrine and dopamine in the synaptic cleft by inhibiting the reuptake of these neurotransmitters and by promoting their release from presynaptic terminals.. AZASITE is a Macrolide Antibiotic that works by Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIPHETAMINE 12.5 and AZASITE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIPHETAMINE 12.5 is: 12.5 mg orally once daily in the morning, may titrate weekly by 12.5 mg to maximum 75 mg/day.. The standard adult dose of AZASITE is: 1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIPHETAMINE 12.5 and AZASITE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIPHETAMINE 12.5 is classified as Category C. First trimester: Possible increased risk of congenital malformations (e.g., heart defects, oral clefts) based on limited human data; animal studies show fetal abnormalities. Second. AZASITE is classified as Category C. Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.